Clinical Trial: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib
Brief Summary: This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
Detailed Summary:
Sponsor: Novartis Pharmaceuticals
Current Primary Outcome: To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg. [ Time Frame: every 8 weeks ]
Original Primary Outcome: To evaluate time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
Current Secondary Outcome: To determine progression-free survival and the response rate of nilotinib in patients with advanced GIST previously treated with imatinib ≥600 mg. [ Time Frame: 6 months ]
Original Secondary Outcome: Same as current
Information By: Novartis
Dates:
Date Received: April 22, 2010
Date Started: September 2008
Date Completion:
Last Updated: February 24, 2017
Last Verified: February 2017